Edition:
United States

Histogenics Corp (HSGX.OQ)

HSGX.OQ on NASDAQ Stock Exchange Capital Market

1.90USD
12 Dec 2017
Change (% chg)

-- (--)
Prev Close
$1.90
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
11,911
52-wk High
$2.40
52-wk Low
$1.45

Chart for

About

Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company's product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue... (more)

Overall

Beta: --
Market Cap(Mil.): $45.73
Shares Outstanding(Mil.): 24.07
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.96 15.25
EPS (TTM): -- -- --
ROI: -- 15.07 33.27
ROE: -- 16.58 16.35

BRIEF-Histogenics Corp announces Q3 loss per share $0.23

* Histogenics Corporation announces third quarter 2017 financial and operating results

Nov 09 2017

BRIEF-Histogenics Corp promotes Stephen Kennedy to COO

* Histogenics Corporation promotes Stephen Kennedy to executive vice president & chief operating officer Source text for Eikon: Further company coverage:

Oct 12 2017

BRIEF-Histogenics says Q2 loss per share $0.25

* Histogenics corporation announces second quarter 2017 financial and operating results

Aug 10 2017

BRIEF-Histogenics on track for top-line one year superiority data, potential BLA filing in Q3 of 2018

* Histogenics completes enrollment for phase 3 clinical trial of neocart® to treat knee cartilage damage

Jun 27 2017

Earnings vs. Estimates